Evidence map›Paper›PMID 31877243›Full record

ArticleBritish journal of pharmacology2020

Fulditoxin, representing a new class of dimeric snake toxins, defines novel pharmacology at nicotinic ACh receptors.

Chun Shin Foo, Chacko Jobichen, Varuna Hassan-Puttaswamy, Zoltan Dekan, Han-Shen Tae, Daniel Bertrand, David J Adams, Paul F Alewood, J Sivaraman, Selvanayagam Nirthanan and 1 more

Open access · hybridAbstract read
In one paragraph

Article in British journal of pharmacology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
1.0field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 21 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. Article
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 5 institutions in 3 countries.

Chun Shin FooProtein Science Laboratory, Department of Biological Sciences, Faculty of Science, National University of Singapore, Singapore, Singapore.
Chacko JobichenDepartment of Biological Sciences, National University of Singapore, Singapore.
Varuna Hassan-PuttaswamyProtein Science Laboratory, Department of Biological Sciences, Faculty of Science, National University of Singapore, Singapore, Singapore.
Zoltan DekanInstitute for Molecular Bioscience, University of Queensland, Brisbane, Queensland, Australia.
Han-Shen TaeIllawarra Health and Medical Research Institute, University of Wollongong, Wollongong, New South Wales, Australia.ORCID 0000-0001-8961-7194
Daniel BertrandHiQScreen Sàrl, Geneva, Switzerland.
David J AdamsIllawarra Health and Medical Research Institute, University of Wollongong, Wollongong, New South Wales, Australia.ORCID 0000-0002-7030-2288
Paul F AlewoodInstitute for Molecular Bioscience, University of Queensland, Brisbane, Queensland, Australia.
J SivaramanDepartment of Biological Sciences, National University of Singapore, Singapore.
Selvanayagam NirthananSchool of Medical Science, Griffith Health Group, Griffith University, Gold Coast, Queensland, Australia.ORCID 0000-0001-9888-8447
R Manjunatha KiniProtein Science Laboratory, Department of Biological Sciences, Faculty of Science, National University of Singapore, Singapore, Singapore.
National University of Singapore · SGThe University of Queensland · AUUniversity of Wollongong · AUGriffith University · AUHiQScreen (Switzerland) · CH

Funding

Australian Research Council Discovery Project Grant (DP150103990) (D.J.A)Australian Research Council DP150103990Griffith Health Institute GRC1009Griffith Health Institute HFC2132940Griffith Health Institute Project Grants (HFC2132940 and GRC1009)(S.N)National Health and Medical Research Council (Australia) APP1072113National Health and Medical Research Council (Australia) Fellowship and Program Grant (APP1072113) (P.F.A)National Medical Research Council, Singapore Grant (NMRC/CBRG/0025/2012) (R.M.K)National Medical Research Council, Singapore NMRC/CBRG/0025/2012National University of Singapore Academic Research Grant (R154000A72-114) (J.S)National University of Singapore R154000A72-114
6 · The paper itself

Abstract

background and purposeAnimal toxins have contributed significantly to our understanding of the neurobiology of receptors and ion channels. We studied the venom of the coral snake Micrurus fulvius fulvius and identified and characterized the structure and pharmacology of a new homodimeric neurotoxin, fulditoxin, that exhibited novel pharmacology at nicotinic ACh receptors (nAChRs). EXPERIMENTAL APPROACH: Fulditoxin was isolated by chromatography, chemically synthesized, its structure determined by X-ray crystallography, and its pharmacological actions on nAChRs characterized by organ bath assays and two-electrode voltage clamp electrophysiology. KEY

resultsFulditoxin's distinct 1.95-Å quaternary structure revealed two short-chain three-finger α-neurotoxins (α-3FNTxs) non-covalently bound by hydrophobic interactions and an ability to bind metal and form tetrameric complexes, not reported previously for three-finger proteins. Although fulditoxin lacked all conserved amino acids canonically important for inhibiting nAChRs, it produced postsynaptic neuromuscular blockade of chick muscle at nanomolar concentrations, comparable to the prototypical α-bungarotoxin. This neuromuscular blockade was completely reversible, which is unusual for snake α-3FNTxs. Fulditoxin, therefore, interacts with nAChRs by utilizing a different pharmacophore. Unlike short-chain α-3FNTxs that bind only to muscle nAChRs, fulditoxin utilizes dimerization to expand its pharmacological targets to include human neuronal α4β2, α7, and α3β2 nAChRs which it blocked with IC CONCLUSIONS AND IMPLICATIONS: Based on its distinct quaternary structure and unusual pharmacology, we named this new class of dimeric Micrurus neurotoxins represented by fulditoxin as Σ-neurotoxins, which offers greater insight into understanding the interactions between nAChRs and peptide antagonists.

Indexed as

Receptors, NicotinicAcetylcholineAmino Acid SequenceAnimalsBungarotoxinsHumansNeurotoxinsNicotinic AntagonistsSnake VenomsAcetylcholineBungarotoxinsNeurotoxinsNicotinic AntagonistsReceptors, NicotinicSnake Venoms

Identifiers

PMID31877243
PMCPMC7070178
OpenAlexW2997439895

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.